drugset

drugset / Trial / NCT03044249

A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

NCT03044249 ↗

Phase 2 Terminated 81 enrolled Mediti Pharma Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

A ten-week study to assess MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

Timeline

Start: 2017-05-04
Primary completion: 2020-01-30
Completion: 2020-01-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY2979165	Unknown	60 mg	Oral

Indications